Safety and Immunogenicity of a Synthetic Nanoparticle-Based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 in Healthy Adults in Switzerland: A Double-Blind, Randomized, Vehicle-Controlled, Phase 1 Study

Juliette Besson, Maxime Karlen, R Audran, Alix Miauton, Hélène Maby–El Hajjami, Loane Warpelin‐Decrausaz, Loredana Sene, Sylvain Schaufelberger, Vincent Faivre, Mohamed Faouzi, Mary‐Anne Hartley, François Spertini, Blaise GentonSSRN 2024 · DOI

BibTeX
@misc{besson2024safety,
  author = {Juliette Besson and Maxime Karlen and R Audran and Alix Miauton and Hélène Maby–El Hajjami and Loane Warpelin‐Decrausaz and Loredana Sene and Sylvain Schaufelberger and Vincent Faivre and Mohamed Faouzi and Mary‐Anne Hartley and François Spertini and Blaise Genton},
  title = {{Safety and Immunogenicity of a Synthetic Nanoparticle-Based, T Cell Priming Peptide Vaccine Against SARS-CoV-2 in Healthy Adults in Switzerland: A Double-Blind, Randomized, Vehicle-Controlled, Phase 1 Study}},
  year = {2024},
  doi = {10.2139/ssrn.4867531},
  howpublished = {SSRN},
}

Loading related content...

Figure